Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma

Cancer

Volumn 104, Issue 10, 2005, Pages 2084-2091

  Thompson, R Houston ^a   Gillett, Michael D ^a   Cheville, John C ^a   Lohse, Christine M ^a   Dong, Haidong ^b   Webster, W Scott ^a   Chen, Lieping ^c   Zincke, Horst ^a   Blute, Michael L ^a   Leibovich, Bradley C ^a   Kwon, Eugene D ^a,b,d  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MAYO CLINIC   (United States)

Author keywords

Costimulation; Immunotherapy; Kidney neoplasms; Neoplasm metastasis; Renal cell carcinoma; T lymphocyte; Tumor biomarker

Indexed keywords

ALPHA INTERFERON; B7 ANTIGEN; B7 H1 ANTIGEN; BIOLOGICAL MARKER; CYTOKINE; INTERLEUKIN 2; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CLEAR CELL CARCINOMA; DRUG TARGETING; FOLLOW UP; FROZEN SECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY TUMOR; LYMPHOCYTE; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; METASTASIS; MULTIVARIATE ANALYSIS; NEPHRECTOMY; PRIORITY JOURNAL; SURVIVAL RATE; T LYMPHOCYTE; TUMOR CELL; TUMOR IMMUNITY; TUMOR NECROSIS;

ANTIGENS, CD; ANTIGENS, CD80; CARCINOMA, RENAL CELL; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; LYMPHOCYTES; MEMBRANE GLYCOPROTEINS; NEOPLASM METASTASIS; PEPTIDES; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 27644562256     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21470     Document Type: Article

References (29)

1. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793-800.
2. Strome SE, Dong H, Tamura H, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 2003;63:6501-6505.
3. Brown JA, Dorfman DM, Ma FR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol. 2003;170: 1257-1266.
4. Dong H, Strome SE, Matteson EL, et al. Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest. 2003;111:363-370.
5. Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003;9:562-567.
6. Dong H, Chen L. B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med. 2003;81:281-287.
7. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA. 2002;99:12293-12297.
8. Hirano F, Kaneko K, Tamura H, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005;65:1089-1096.
9. Bromwich EJ, McArdle PA, Canna K, et al. The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. Br J Cancer. 2003;89:1906-1908.
10. Nakano O, Sato M, Naito Y, et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 2001;61:5132-5136.
11. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21:3127-3132.
12. Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA. 2004;101:17174-17179.
13. Storkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma: workgroup no. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80:987-989.
14. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol. 1997;183:131-133.
15. Lohse CM, Blute ML, Zincke H, Weaver AL, Cheville JC. Comparison of standardized and nonstandardized nuclear grade of renal cell carcinoma to predict outcome among 2,042 patients. Am J Clin Pathol. 2002;118:877-886.
16. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002;168:2395-2400.
17. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5:1365-1369.
18. Dong H, Zhu G, Tamada K, Flies DB, van Deursen JM, Chen L. B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. Immunity. 2004;20:327-336.
19. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol. 2004;4: 336-347.
20. Wintterle S, Schreiner B, Mitsdoerffer M, et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res. 2003;63:7462-7467.
21. Blank C, Brown I, Peterson AC, et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004;64:1140-1145.
22. Ficarra V, Martignoni G, Maffei N, et al. Original and reviewed nuclear grading according to the Fuhrman system: a multivariate analysis of 388 patients with conventional renal cell carcinoma. Cancer. 2005;103:68-75.
23. Uzzo RG, Rayman P, Kolenko V, et al. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin Cancer Res. 1999;5:1219-1229.
24. Nakagomi H, Pisa P, Pisa EK, et al. Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Int J Cancer. 1995;63:366-371.
25. Copland JA, Luxon BA, Ajani L, et al. Genomic profiling identifies alterations in TGFbeta signaling through loss of TGFbeta receptor expression in human renal cell carcinogenesis and progression. Oncogene. 2003;22:8053-8062.
26. Lahn M, Fisch P, Kohler G, et al. Pro-inflammatory and T cell inhibitory cytokines are secreted at high levels in tumor cell cultures of human renal cell carcinoma. Eur Urol. 1999; 35:70-80.
27. Alexander JP, Kudoh S, Melsop KA, et al. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res. 1993;53:1380-1387.
28. Li X, Liu J, Park JK, et al. T cells from renal cell carcinoma patients exhibit an abnormal pattern of kappa B-specific DNA-binding activity: a preliminary report. Cancer Res. 1994;54:5424-5429.
29. Kudoh S, Redovan C, Rayman P, et al. Defective granzyme B gene expression and lytic response in T lymphocytes infiltrating human renal cell carcinoma. J Immunother. 1997;20: 479-487.